MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Arena Pharmaceuticals (NASDAQ: ARNA)
Organization & Developments: Arena
Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH)
Organization & Developments: Longboard Pharmaceuticals
Parents
Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH)
Children
2020: Arena's Amit Munshi spins out his neuro sub into a biotech startup, with $56M for the baptism
2022: Longboard Pharmaceuticals: Arena Team's Next Act Is Flying Under The Radar_ seekingalpha.com
2023: Undervalued Arena Spin-Out Has 2 Data Catalysts Due In 2023
2024: Behind The Huge Rally In Longboard Pharmaceuticals_ seekingalpha.com
2024: Behind The Huge Rally In Longboard Pharmaceuticals_seekingalpha.com
2024: Denmark's Lundbeck bets on epilepsy drug with $2.6 billion Longboard deal
2024: Longboard Pharma: Excellent Data In Epileptic Seizures, But We Are A Little Late Now_seekingalpha.com
2024: Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management
2024: Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely_seekingalpha.com
2024: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline
2024: Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition
2024: My Strategy For Longboard Pharmaceuticals After Its Big Run
Jumps
Finance & Acquisitions: Longboard Pharmaceuticals
Key People: Longboard Pharmaceuticals